![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1571000
¾È±¸Ç¥¸éÁúȯ ½ÃÀå(2024³â)2024 Ocular Surface Disease Survey Report |
¼¼°èÀÇ ¾È±¸Ç¥¸éÁúȯ ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ÁúȯÀÇ °³¿ä¿Í ÇÔ²² ºÎ¹®º° µ¿Çâ, Ä¡·á¹ý, Áø´Ü¾à, »ý¹°Á¦Á¦ÀÇ »ç¿ë µ¿Ç⠵ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
Market Scope surveyed ophthalmologists and optometrists in the United States and Western Europe during July and August 2024 to measure patients they were seeing and screening for ocular surface disease; adoption of treatments; and insight into the latest market trends.
Practitioners from most specialties (cataract, refractive, cornea, glaucoma, and comprehensive) who self-registered on Market-Scope.com were invited to participate in an annual sponsored survey on ocular surface disease.
An email invitation was sent on July 26, 2024, and a last call went out on Aug. 23, 2024. We received 149 total complete, unique responses-116 from the US and 33 from WE. All results were calculated based on respondent count; because not all questions were applicable to all providers, the respondent count (n) may vary throughout the survey.
Survey reports are strictly a summary analysis of the reported data, and no additional extrapolation to the overall market was performed. All survey data are de-identified and maintained on a secure server.
Questions included in the survey were developed by Market Scope in combination with companies that sponsor the survey. Question topics included, but were not limited to, the following: